HLB Pharmaceutical Co. Ltd (047920) — Cash Flow-to-Debt Ratio
HLB Pharmaceutical Co. Ltd (047920) has a Cash Flow-to-Debt Ratio of 0.04x as of September 2025, meaning its operating cash flow of ₩1.86 Billion could theoretically repay 0% of its total liabilities (₩46.98 Billion) in one year. Explore investment intensity of HLB Pharmaceutical Co. Ltd to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
HLB Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for HLB Pharmaceutical Co. Ltd across 11 annual periods. Also explore 047920 current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year debt coverage analysis for HLB Pharmaceutical Co. Ltd. For market capitalisation and broader financial context, see 047920 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.16x | ₩6.84 Billion | ₩41.53 Billion | ▲ +147.8% |
| 2023 | -0.34x | ₩-18.32 Billion | ₩53.20 Billion | ▼ -601.0% |
| 2022 | -0.05x | ₩-2.76 Billion | ₩56.25 Billion | ▼ -83.1% |
| 2021 | -0.03x | ₩-1.32 Billion | ₩49.25 Billion | ▼ -344.3% |
| 2020 | -0.01x | ₩-403.36 Million | ₩66.80 Billion | ▼ -113.0% |
| 2019 | 0.05x | ₩1.35 Billion | ₩29.04 Billion | ▲ +150.9% |
| 2018 | -0.09x | ₩-1.78 Billion | ₩19.42 Billion | ▼ -168.9% |
| 2017 | -0.03x | ₩-784.30 Million | ₩23.04 Billion | ▼ -256.8% |
| 2016 | -0.01x | ₩-213.11 Million | ₩22.34 Billion | ▲ +84.3% |
| 2015 | -0.06x | ₩-769.59 Million | ₩12.67 Billion | ▼ -165.4% |
| 2014 | 0.09x | ₩1.54 Billion | ₩16.62 Billion | — |